imipramine and debrisoquin

imipramine has been researched along with debrisoquin in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (40.00)	18.7374
1990's	3 (30.00)	18.2507
2000's	2 (20.00)	29.6817
2010's	1 (10.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Brøsen, K; Gram, LF; Kragh-Sørensen, P	1
Brøsen, K; Meyer, UA; Zeugin, T	1
Balant, LP; Balant-Gorgia, AE; Garrone, G	1
Brøsen, K	1
Küpfer, A; Meyer, JW; Woggon, B	1
Bech, P; Bertilsson, L; Brøsen, K; Gram, LF; Klysner, R; Otton, SV	1
Chiba, K; Echizen, H; Ishizaki, T; Kikuchi, Y; Koyama, E	1
Guo, B; He, MM; Li, C; Liu, H; Shen, H; Wang, L; Wrighton, SA	1

Reviews

1 review(s) available for imipramine and debrisoquin

Article	Year
The relationship between imipramine metabolism and the sparteine oxidation polymorphism. Danish medical bulletin, 1988, Volume: 35, Issue:5 Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Imipramine; Isoenzymes; Microsomes, Liver; Oxidation-Reduction; Oxidoreductases; Polymorphism, Genetic; Sparteine	1988

Trials

1 trial(s) available for imipramine and debrisoquin

Article	Year
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. European journal of clinical pharmacology, 1986, Volume: 30, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Debrisoquin; Depression; Desipramine; Female; Humans; Hydroxylation; Imipramine; Isoquinolines; Kinetics; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Sparteine	1986

Article

Year

Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

European journal of clinical pharmacology, 1986, Volume: 30, Issue:6

Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Debrisoquin; Depression; Desipramine; Female; Humans; Hydroxylation; Imipramine; Isoquinolines; Kinetics; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Sparteine

1986

Other Studies

8 other study(ies) available for imipramine and debrisoquin

Article	Year
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Therapeutic drug monitoring, 1991, Volume: 13, Issue:2 Topics: Administration, Oral; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Chromatography, Thin Layer; Debrisoquin; Desipramine; Drug Interactions; Humans; Imipramine; Male; Mephenytoin; Phenotype; Quinidine; Sparteine	1991
Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clinical pharmacology and therapeutics, 1991, Volume: 49, Issue:6 Topics: Antibodies; Cells, Cultured; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; DNA; Humans; Imipramine; Isoenzymes; Kidney; Kinetics; Methotrimeprazine; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Polymorphism, Genetic; Quinidine; Sparteine; Transfection	1991
High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Therapeutic drug monitoring, 1989, Volume: 11, Issue:4 Topics: Aged; Clomipramine; Debrisoquin; Depressive Disorder; Female; Humans; Hydroxylation; Imipramine; Middle Aged; Monitoring, Physiologic; Phenotype; Psychiatric Status Rating Scales	1989
Importance of oxidative polymorphism on clinical efficacy and side-effects of imipramine--a retrospective study. Pharmacopsychiatry, 1988, Volume: 21, Issue:6 Topics: Debrisoquin; Depressive Disorder; Female; Humans; Imipramine; Male; Mephenytoin; Middle Aged; Oxidation-Reduction	1988
Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipramine, desipramine, their 2-hydroxylated metabolites, and imipramine N-oxide in human plasma and urine: preliminary application to oxidation pharmacogeneti Therapeutic drug monitoring, 1993, Volume: 15, Issue:3 Topics: Arylsulfatases; Calibration; Chromatography, High Pressure Liquid; Debrisoquin; Desipramine; Electrochemistry; Glucuronidase; Humans; Hydroxylation; Imipramine; Male; Oxidation-Reduction; Phenotype; Psychotropic Drugs; Sensitivity and Specificity; Sparteine; Time Factors; Tranquilizing Agents	1993
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:8 Topics: Atomoxetine Hydrochloride; Cocaine; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dextromethorphan; Enzyme Inhibitors; Ethanolamines; Fluoxetine; Humans; Hydroxylation; Imipramine; Kinetics; Microsomes; Molecular Structure; Nortriptyline; Polymorphism, Single Nucleotide; Propylamines; Quinidine; Recombinant Proteins; Thioridazine; Tramadol	2007